Pacer Advisors
MRNA icon

Pacer Advisors’s Moderna MRNA Stock Holding History

Pacer Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.28M Buy
75,339
+57,958
+333% +$3M 0.01% 677
2026
Q1 		$883K Sell
17,381
-9,865
-36% -$460K ﹤0.01% 1264
2025
Q4 		$803K Sell
27,246
-36,619
-57% -$995K ﹤0.01% 1569
2025
Q3 		$1.65M Sell
63,865
-767
-1% -$21.4K ﹤0.01% 1177
2025
Q2 		$1.78M Buy
64,632
+47,329
+274% +$1.25M ﹤0.01% 1068
2025
Q1 		$491K Sell
17,303
-9,473
-35% -$336K ﹤0.01% 1455
2024
Q4 		$1.11M Sell
26,776
-20,901
-44% -$999K ﹤0.01% 1301
2024
Q3 		$3.19M Buy
47,677
+2,379
+5% +$218K 0.01% 786
2024
Q2 		$5.38M Buy
45,298
+3,930
+10% +$497K 0.01% 567
2024
Q1 		$4.41M Sell
41,368
-4,024
-9% -$406K 0.01% 602
2023
Q4 		$4.51M Sell
45,392
-7,951
-15% -$669K 0.01% 590
2023
Q3 		$5.51M Sell
53,343
-27,538
-34% -$3.07M 0.02% 448
2023
Q2 		$9.83M Sell
80,881
-18,448
-19% -$2.46M 0.04% 384
2023
Q1 		$15.3M Sell
99,329
-1,126,738
-92% -$186M 0.07% 293
2022
Q4 		$220M Buy
1,226,067
+57,020
+5% +$9.32M 1.13% 8
2022
Q3 		$138M Buy
1,169,047
+149,879
+15% +$22.7M 0.96% 23
2022
Q2 		$146M Buy
1,019,168
+438,198
+75% +$62.6M 1.08% 10
2022
Q1 		$100M Buy
580,970
+465,401
+403% +$78.4M 0.82% 12
2021
Q4 		$29.4M Buy
115,569
+83,543
+261% +$24.4M 0.3% 45
2021
Q3 		$12.3M Sell
32,026
-43,512
-58% -$16M 0.16% 142
2021
Q2 		$17.8M Buy
75,538
+61,087
+423% +$10.9M 0.25% 56
2021
Q1 		$1.89M Sell
14,451
-1,064
-7% -$154K 0.03% 532
2020
Q4 		$1.62M Sell
15,515
-13,985
-47% -$1.41M 0.03% 508
2020
Q3 		$2.09M Buy
29,500
+29,190
+9,416% +$2.04M 0.04% 401
2020
Q2 		$20K Buy
+310
New +$17K ﹤0.01% 875

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Pacer Advisors's MRNA Position: Q2 2026 in Review

Pacer Advisors increased its Moderna (MRNA) stake by 333% in Q2 2026, buying an estimated $3M and bringing the position to 75,339 shares worth $5.28M. The position accounts for 0.01% of the portfolio, ranked #677.

Pacer Advisors first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $220M in Q4 2022. 787 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Pacer Advisors held 75,339 shares of Moderna worth $5.28M as of Q2 2026.
  • Pacer Advisors bought 57,958 Moderna shares in Q2 2026, an estimated $3M.
  • Moderna made up 0.01% of Pacer Advisors's portfolio in Q2 2026, its #677 holding.
  • Pacer Advisors first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Pacer Advisors's Moderna position peaked at $220M in Q4 2022.
  • 787 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.